Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Background Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizum...

Full description

Bibliographic Details
Main Authors: Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen
Format: Article
Language:English
Published: Wiley 2016-10-01
Series:Molecular Oncology
Subjects:
Predictive model
Angiotensin
Vascular normalization
Immune activation
Anti-angiogenic treatment
Glioblastoma
Online Access:https://doi.org/10.1016/j.molonc.2016.05.005

Internet

https://doi.org/10.1016/j.molonc.2016.05.005

Similar Items